Bioavailability Study of Ondansetron Orally Disintegrating Tablets Under Fasting Conditions

NCT ID: NCT00654277

Last Updated: 2008-04-11

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 32 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2002-08-31
• Study Completion Date: 2002-09-30

Brief Summary

To compare the single-dose bioavailability of Ondansetron 8 mg oDT and Zofran 8 mg ODT

Detailed Description

To Compare the single-dose bioavailability of Kali's Ondansetron 8 mg ODT with that of GlaxoSmithKine's Zofran 8 mg ODT under fasting conditions

Conditions

Healthy

Keywords

bioequivalence; Ondansetron ODT; Fasting; To determine bioequivalence under fasting conditions

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Blinding Strategy: NONE

Study Groups

A

Subjects received Kali formulated products under fasting conditions

Group Type: EXPERIMENTAL

Ondansetron

Intervention Type: DRUG

ODT, 8 mg, single-dose

B

Subjects received GlaxoSmithKine product under fasting conditions

Group Type: ACTIVE_COMPARATOR

Zofran

Intervention Type: DRUG

ODT, 8 mg, fasting conditions

Interventions

Ondansetron

ODT, 8 mg, single-dose

Intervention Type: DRUG

Zofran

ODT, 8 mg, fasting conditions

Intervention Type: DRUG

Other Intervention Names

Zofran; Ondansetron ODT

Eligibility Criteria

Inclusion Criteria

• Subjects meeting all of the following criteria may be included in the study.
• Availability of subject for the entire study period and willingness to adhere to protocol requirements as evidenced by the informed consent form duly signed by the subject.
• Males and Females aged from 18 to 50 years ol with a body mass index (BMI)within 19-30; demographic data (sex, age, ethnic group, body weight, height and smoking habits) will be recorded and reported in the final report.
• Clinical laboratory values within the laboratory's stated normal range; if not within this range, they must be without any clinical significance and must be recorded as such in the CRF (laboratory tests are presented in section 7.1.3.
• Healthy according to the laboratory results and physical examination.
• Normal cardiovascular function according to ECG.
• Non or ex-smokers.

Exclusion Criteria

• Significant history of hypersensitivity to ondansetron or any related products as well as severe hypersensitivity reactions (like angioedema) to any drugs.
• Presence or history of significant gastrointestinal, liver or kidney disease, or any conditions known to interfere with the absorption, distribution, metabolism or excretion of drugs or known to potentiate or predispose to undesired effects.
• Presence or history of significant cardiovascular, pulmonary, hematologic, neurologic, psychiatric, endocrine, immunologic or dermatologic disease.
• Females who are pregnant, lactating or are likely to become pregnant during the study phases.
• Females of childbearing potential who refuse to use an acceptable contraceptive regimen throughout the body.
• Positive pregnancy test before and during the study.
• Maintenance therapy with any drug, or significant history or drug dependancy, alcohol abuse (>3 units of alcohol per day, intake of excessive alcohol, acute or chronic), or serious psychological disease.
• Any clinically significant illness in the previous 28 days before day 1 of this study.
• Use of enzyme-modifying drugs in the previous 28 days before 1 day of this study (all barbiturates, corticosteroids, phenylhydantoins, etc.).
• Participation in another clinical trial in the previous 28 days before day 1 of this study.
• Donation of 500 mL of blood (Canadian Blood Services, Hema-Quebec, clinical studies, etc.) in the previous 56 days before day 1 of this study.
• Positive urine screening of drugs of abuse (drug names are presented in section 7.1.4).
• Positive results to HIV, HBsAg or anti-HCV tests.
• History of fainting upon blood sampling.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 50 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Algorithme Pharma Inc

INDUSTRY

Sponsor Role: collaborator

Par Pharmaceutical, Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Par Pharmaceutical, Inc.

Principal Investigators

Christian Aumais

Role: PRINCIPAL_INVESTIGATOR

Algotithme Pharma Inc

Other Identifiers

ODO-P2-158

Identifier Type: -

Identifier Source: org_study_id